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Abstract
Background: Both diabetes and obesity syndromes are recognized to promote lumbar vertebral instability, premature
osteodegeneration, exacerbate progressive osteoporosis and increase the propensity towards vertebral degeneration,
instability and deformation in humans.
Methods:  The influences of single-gene missense mutations, expressing either diabetes (db/db) or obese (ob/ob)
metabolic syndromes on vertebral maturation and development in C57BL/KsJ mice were evaluated by radiological and
macro-morphometric analysis of the resulting variances in osteodevelopment indices relative to control parameters
between 8 and 16 weeks of age (syndrome onset @ 4 weeks), and the influences of low-dose 17-B-estradiol therapy on
vertebral growth expression evaluated.
Results: Associated with the indicative genotypic obesity and hyper-glycemic/-insulinemic states, both db/db and ob/ob
mutants demonstrated a significant (P ≤ 0.05) elongation of total lumbar vertebrae column (VC) regional length, and
individual lumbar vertebrae (LV1-5) lengths, relative to control VC and LV parameters. In contrast, LV1-5 width indices
were suppressed in db/db and ob/ob mutants relative to control LV growth rates. Between 8 and 16 weeks of age, the
suppressed LV1-5 width indices were sustained in both genotype mutant groups relative to control osteomaturation
rates. The severity of LV1-5 width osteosuppression correlated with the severe systemic hyperglycemic and
hypertriglyceridemic conditions sustained in ob/ob and db/db mutants. Low-dose 17-B-estradiol therapy (E2-HRx: 1.0 ug/
0.1 ml oil s.c/3.5 days), initiated at 4 weeks of age (i.e., initial onset phase of db/db and ob/ob expressions) re-established
control LV 1–5 width indices without influencing VC or LV lengths in db/db groups.
Conclusion: These data demonstrate that the abnormal systemic endometabolic states associated with the expression
of db/db and ob/ob genomutation syndromes suppress LV 1–5 width osteomaturation rates, but enhanced development
related VC and LV length expression, relative to control indices in a progressive manner similar to recognized human
metabolic syndrome conditions. Therapeutic E2 modulation of the hyperglycemic component of diabetes-obesity
syndrome protected the regional LV from the mutation-induced osteopenic width-growth suppression. These data
suggest that these genotype mutation models may prove valuable for the evaluation of therapeutic methodologies
suitable for the treatment of human diabetes- or obesity-influenced, LV degeneration-linked human conditions, which
demonstrate amelioration from conventional replacement therapies following diagnosis of systemic syndrome-induced
LV osteomaturation-associated deformations.
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Background
Both Type 2 (NIDDM) diabetes and obesity represent dys-
regulated glucometabolic syndrome conditions in
humans and experimental models [1-8]. The conse-
quences of uncontrolled (non-corrected) hyperglycemic
and hypertriglyceridemic systemic conditions have severe
consequences on osteodevelopment and maturation indi-
ces, including suppressed skeletal development [1-3],
increased incidence of osteopenia and osteoporosis [4-9],
altered osteocytic proliferation rates [2,4,9,10], impaired
bone healing potential [6], decreased osteoid tensile
strength [1] and compromised osteomaturation indices
[2,7,8,10-14]. Both diabetes (db/db) and obesity (ob/ob)
syndromes in C57BL/KsJ mice are induced by inherited
single-gene mutations, characterized by systemic and cel-
lular hypercaloric Type II diabetes-obesity states [15-19].
These syndromes become expressed during the peripuber-
ital period of life, at approximately 3–4 weeks of age, with
subsequent progressive exacerbation of the syndrome
conditions with age, similar to the progression from onset
of youth [20] to adult maturity [21-23] human diabetes
conditions. The resulting obese phenotypes [16-18] are
related to a genetic mutation-induced leptin membrane
receptor protein/ ligand misexpression (Table 1), generat-
ing hyperphagic experimental models which exhibit pro-
gressive body mass expansion, hyperglycemia,
hyperinsulinemia, hypertriglyceridemia and premature
cellular lipoinvolution, including skeletal osteopenia and
chronic osteodegeneration [8,16-19,23-27]. The progres-
sive, chronic metabolic compromise of cellular matura-
tion and proliferation indices culminates in suppressed
osteomaturation [28,29], cytostructural compromise[30],
suppressed growth expression [1,29], premature oste-
oporosis [8,31-34], increased fracture susceptibility [34-
38] and skeletal deformation [1-3,8].
Recent reports suggest that the severity of lumbar vertebral
(LV) osteodegeneration and osteoporosis is enhanced in
both diabetics and obese patients exhibiting blatant sys-
temic syndrome aberrations accompanied by chronic
lower back discomfort or deformation [3-5,8,11]. In gen-
eral, conventional pharmacotherapeutic replacement
regimes fail to completely ameliorate progressive LV dete-
rioration in afflicted patients [8,10,31-38]. The lack of an
identified experimental model that demonstrates progres-
sive osteodegeneration following the expression of diabe-
tes or obese states has impeded the evaluation of
interventional therapeutic approaches focused on the alle-
viation of progressive LV osteodegeneration or destabili-
zation [32-40]. The current studies were designed to
evaluate the influences of diabetes (db/db) and obese (ob/
ob) genotype-mutations towards the induction of VC and
LV osteo-retardation and degeneration, recognized as
chronic human syndrome complications [8,37], and the
progressive influences of the syndrome conditions on LV
morphometric and radiological indices associated with
the duration of mutation expression in the C57BL/-KsJ
murine model.
Methods
Animals
Adult, female C57BL/ KsJ mice (Jackson Laboratory, Bar
Harbor, ME derived), between 4 and 16 weeks of age were
used in these studies. Littermate controls (designated as
mixed +/+ and +/? normal phenotypes/genotypes), as well
as littermate diabetes (db/db) and obese (ob/ob)-mutant
(homozygous recessive) genotypes (Table 1), were pair
matched for phenotype, tissue sampling and systemic
metabolic indices analyses (i.e., blood glucose, serum
insulin and triglyceride concentrations) comparisons dur-
ing the course of these studies (Table 2). All mice were
housed five per cage, grouped according to genotype,
under controlled environmental conditions (23 C), with
an established photoperiod of 12 hr light/day (lights on:
0600 hr) [29]. Blood glucose levels (Ames Glucometer
method), serum insulin and triglycerides levels [26,29]
and body weights were monitored for each of the desig-
nated 8 and 16-week-old experimental age groups as pre-
viously described [26,29,41]. Animals exhibiting either
lean (≤ 15 grams) or obese (≥ 25 grams) phenotypes (con-
trols: ± 20 grams) and pronounced systemic hyperglyc-
emia (≥ 200 mg/dl) relative to controls (≤150 mg/dl) by
8 weeks of age (Table 1) were considered as overt, Type 2
NIDDM obese (ob/ob) or diabetes (db/db) groups [16,36],
Table 1: Comparison of genotype mutation-related deficiencies in C57BL/KsJ Mice
Genotype Mutation Characteristic Syndrome Indices
(+/?) Controls (Heterozygous Littermates) None Normal
(db/db) Diabetes (Leprdb) Leptin Membrane Receptor (lf) 
Missense Mutation Defect (leptin 
insensitive)
Obese, Type 2 NIDDM (severe 
hyperglycemia & hyperinsulinemia)
(ob/ob)O b e s e  ( L e p ob) Leptin Protein Deficient (leptin gene 
mutation; leptin sensitive)
Obese, Type 2NIDDM (Moderate 
glycemia & insulin insensitive)
Comparison between genotypic indices induced by the indicate mutations, relative to normal littermate controls, and the attributed protein 
expression deficits associated with metabolic syndrome expression complications when expressed on the C57BL/KsJ murine background strain. An 
age-related exacerbation of the severity of mutation-induced metabolic/structural complications occurs for each genotype mutation.BMC Musculoskeletal Disorders 2006, 7:10 http://www.biomedcentral.com/1471-2474/7/10
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with the continued expression of these indices denoted
through the chronic 16-week old (Table 2) age group
experimental periods.
Radiographic and morphometric analysis of lumbar 
vertebral column (VC) and individual vertebrae (LV) 
maturation variances
At 8 and 16 weeks of age, each designated genotype group
was subjected to light methoxyflurane (Parke-Davis,
Detroit, MI) inhalation (45 sec exposure) anesthesia prior
to radiographic imaging analysis of lumbar vertebral col-
umn (VC) regional length measurements, as well as indi-
vidual lumbar vertebrae (LV) length and width
measurements. A complete lumbar vertebral radiographic
(1/30-1/24 sec exposure at a 40 KV/200 amp setting)
image was captured on radiographic (Kodak, Rochester,
NY) plate film, developed and the respective measure-
ments of VC and individual LV 1–5 length and width indi-
ces determined using an Olympus flat-bed light-optics
graphics recording unit connected to a data processing
computer for statistical tabulation and analysis of mor-
phometric measurement parameters [42]. All bone meas-
urements were determined by enhanced digital image
analysis of individual radiographs utilizing identified
lumbar vertebral column location landmarks at both 8
and 16 weeks of age for all control and genotype-muta-
tion designated groups. Morphometric data were col-
lected, tabulated, analyzed and compared for intergroup
differences relative to specified group mutation type
(Table 1), age (duration) of mutation expression (Table 2)
as well as LVC and LV variances.
Estradiol treatments (E2-HRx)
17-B-estradiol (E2: 1 ug/ 3.5 days) was dissolved in ses-
ame oil (0.1 ml) for subcutaneous injections (HRx: indi-
cated as Day 0 of 3.5 day intervals) initiated at 3 weeks (21
days: weaning) of age. The oil (sesame: Sigma) vehicle
(0.1 ml) served as the sham-control injection procedure as
previously described [18,24]. These temporal dose
regimes were selected based on previous studies indicat-
ing the restoration of diestral (i.e., control baseline) sys-
temic ovarian steroid concentrations in hypogonadal db/
db mutants following initiation of the E2-HRx therapies
prior to the overt onset of the diabetes-associated syn-
drome [17,18].
Statistical analysis
Values for body weights, bone morphometrics and sys-
temic endometabolic indices were expressed as group
means (± SEM) for the designated genotype groups. Inter-
group and intra-group differences were determined using
the Student's T-test exam, with a p ≤ 0.05 accepted as rep-
resenting statistical differences for the specified parame-
ter.
Results
Genotype (mutation)-related influences on body mass and 
systemic endometabolic indices
Between 8 and 16 weeks of age, control groups demon-
strated stable body weights in association with systemic
euglycemia, normoinsulinemia and basal circulating trig-
lyceride (triacylglycerol) levels (Table 2). In contrast, both
db/db and ob/ob mutation expressions induced significant
increases in body masses and systemic endometabolic
indices between 8 and 16 weeks of age relative to param-
eters (Table 2).
Radiographic and morphometric analysis of LVC and LV 1–
5 maturation variances associated with genotype 
mutation expression
Radiographic (Figure 1) and morphometric (Figure 2)
analysis of total LVC length and average LV 1–5 length
and width indices demonstrated variances in VC matura-
tion and growth indices associated with db/db and ob/ob
mutation expressions in C57BL/KsJ groups. Compared to
control growth indices (Figure 2), all genotype mutation
groups demonstrated significant increases in average lum-
bar VC length measurements relative to control indices at
Table 2: Comparisons between phenotypic and systemic endocrine/metabolic indices Induced by expression of diabetes (db/db) and 
obese (ob/ob) mutations in C57BL/KsJ mice
Parameter Age(weeks) Controls Diabetes Obese
Body Weight (g) 8 21.1 ± 0.3 (16) *33.7 ± 0.8 (16) *37.0 ± 1.3 (16)
16 25.2 ± 0.5 (12) *41.0 ± 2.4 (8) *59.3 ± 1.2 (10)
Blood Glucose (mg/dl) 8 108.6 ± 7.7 (12) *278.5 ± 22.6 (12) *178.9 ± 15.4 (12)
16 128.3 ± 7.9 (8) *356.6 ± 37.6 (8) *150.9 ± 5.8 (8)
Serum Insulin (pg/ml) 8 1184.3 ± 121.4 (12) *3862.8 ± 231.7 (12) *2342.9 ± 186.4 (12)
16 1386.0 ± 132.0 (8) *3300.0 ± 181.0 (8) *2000.0 ± 150.0 (8)
Serum Triglycerides (mg/ml) 8 162.0 ± 18.0 (12) *300.0 ± 50.0 (12) *300.0 ± 53.0 (12)
16 162.0 ± 24.0 (8) *300.0 ± 83.0 (8) *300.0 ± 43.0 (8)
Comparisons between indicated phenotype and systemic endocrine/metabolic parameters in control, diabetes- or obese-mutant C57BK/KsJ mice at 
8 and 16 weeks of age are demoted as group means (± SEM) for the designated number (N) of animals per group. Significant (P ≤ 0.05) intergroup 
differences (i.e. control v.s. genotype group values) at the designated age are indicated by asterisks (*).BMC Musculoskeletal Disorders 2006, 7:10 http://www.biomedcentral.com/1471-2474/7/10
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8 and 16 weeks of age (Figure 2) in association with
hypercaloric endometabolic indices and expanded body
masses (Table 2). By 16 weeks of age, the progressive and
cumulative influences of the db/db  and ob/ob  mutation
syndromes promoted exaggerated VC and LV lengths, but
diminished individual LV 1–5 width expression, relative
to control groups (Figure 2).
Influences of 17-B-estradiol (E2) therapy (HRx) on VC and 
LV 1–5 growth indices in diabetes (db/db) genotype mutant 
groups
The therapeutic (0.1 ug/0.1 ml oil vehicle: sc injection @
3.5 day intervals) re-establishment of normoglycemia
(Table 3) by the administered E2-HRx regime following
expression of the db/db syndrome did not influence total
VC length indices, or individual LV 1–5 length parame-
ters, in the mutation group or in controls (Figure 3) at 8
weeks of age (i.e., 4 weeks post-onset of E2-HRx). In addi-
tion, at 16 weeks of age, the average LV 1–5 lengths of
both oil- and E2-HRx db/db groups remained elongated
relative to littermate control indices. In contrast, E2-HRx
promoted a significant increase in average LV 1–5 width
in the db/db  mutant groups, relative to oil-HRx (sham
vehicle injections) db/db mutants, and comparable to lit-
termate controls (Figure 3) at both 8 and 16 weeks of age.
Discussion
The results of the current studies demonstrate that the
expression of diabetes and obese metabolic syndromes in
C57BL/KsJ mice, attributable to the expression of single-
gene mutations, compromises lumbar vertebral osteomat-
uration rates and individual LV 1–5 growth indices, cul-
minating in variant VC development similar to chronic
Representation of average lumber vertebral column (VC)  lengths, as well as individual lumber vertebrae (LV) length  and width indices, are denoted for control (+/?), obese (ob/ ob) and diabetes (db/db) mutant genotypes as groups means  (± SEM) at 8 and 16 weeks of age Figure 2
Representation of average lumber vertebral column (VC) 
lengths, as well as individual lumber vertebrae (LV) length 
and width indices, are denoted for control (+/?), obese (ob/
ob) and diabetes (db/db) mutant genotypes as groups means 
(± SEM) at 8 and 16 weeks of age. Significant (P ≤ 0.05) inter-
group differences (i.e., control v.s. genotype mutant type) at 
each designed age are denoted by asterisks (*). Age-depend-
ent (i.e., 8 v.s. 16 week values for the same genotype) intra-
group differences are denoted by #.
Radiological comparisons between the lumbar vertebral seg- ments (LV 1–5) for control, obese (ob/ob) and diabetes (db/ db) genotype-mutants groups are represented (x12.5) as indi- cators of length and width index parameters measured rela- tive to the severity of diabetes-obesity syndrome aberrations  for body weight and systemic endocrine/metabolic (Table 2)  indices Figure 1
Radiological comparisons between the lumbar vertebral seg-
ments (LV 1–5) for control, obese (ob/ob) and diabetes (db/
db) genotype-mutants groups are represented (x12.5) as indi-
cators of length and width index parameters measured rela-
tive to the severity of diabetes-obesity syndrome aberrations 
for body weight and systemic endocrine/metabolic (Table 2) 
indices.BMC Musculoskeletal Disorders 2006, 7:10 http://www.biomedcentral.com/1471-2474/7/10
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human syndrome complications [8,31,33,36,37,39]. The
radiological and morphometric indications of pro-
nounced VC and LV 1–5 length indices, contrasted with
diminished LV 1–5 width parameters, in these experimen-
tal models are suggestive causes of the recognized
increases of vertebral fracture, osteoporosis and torsion
stress-induced dislocation susceptibilities in humans
experiencing chronic diabetes or obesity-related systemic
metabolic, endocrine or nutritional compromise [8,32-
35,37,38]. The pronounced, progressive suppression of
LV 1–5 width maturation, but pronounced individual LV
and total VC regional elongation, indices occurred under
the systemic influences of hyperglycemic, hyperinsuline-
mic and hyperlipidemic endocrine/metabolic stimula-
tion. These data indicate that in these novel experimental
models of dysregulated metabolic syndromes, variances
in VC and LV growth expressions may be evaluated which
are recognized to be shared with chronic human syn-
drome complications [8,37,39]. The restoration of nor-
mal LV 1–5 width indices in db/db mutants following E2-
HRx indicates that correction of the glucometabolic dis-
turbances with characterize the hypogonadal mutant
model [28-30] re-establishes osteomaturation indices
under persistent missense mutation (Table 1) expression
influences [15,16]. These results indicate that the thera-
peutic re-establishment of a homeostatic systemic gluco-
metabolic environment in db/db  mutants supports the
expression of normalized LV 1–5 width osteomaturation
and VC stabilization, and counter-regulates the hypergly-
cemia-promoted susceptibilities to osteoporosis and VC
destabilization resulting from chronic diabetes syndrome
influences [1-5,8,18].
Multiple tissue types and cytometabolic expression events
are recognized to be influenced by the systemic, intersti-
tial and pericellular environmental aberrations which
characterize glucometabolic, genotype mutation syn-
dromes [4,8,16,18,23,33,37]. In addition to the intrinsic
genome-directed influences on normal bone growth
Influences on control (+/?) and diabetes (db/db)-mutant  C57BL/KsJ group average lumbar vertebrae (LV) length and  width indices following oil- or E2-HRx regimes at 8 and 16  weeks of age Figure 3
Influences on control (+/?) and diabetes (db/db)-mutant 
C57BL/KsJ group average lumbar vertebrae (LV) length and 
width indices following oil- or E2-HRx regimes at 8 and 16 
weeks of age. All values are denoted as groups means (± 
SEM), with significant (P ≤ 0.05) intergroup (i.e. control v.s. 
diabetes genotypes for indicated HRx regimes) differences 
are denoted by asterisks (*)
Table 3: Influences of E2-HRx on body weights and blood glucose levels in control and diabetes-mutant C57BL/KsJ mice
Group Age (weeks) HRx Parameters
Body Weight(g) Blood Glucose(mg/dl)
Control 8 Oil 21.1 ± 0.3 109 ± 8
E2 21.8 ± 2 118 ± 8
Diabetes 8 Oil 33.7 ± 0.8* 278.5 ± 23*
E2 34.2 ± 0.7* 261.1 ± 16*
Control 16 Oil 25.2 ± 0.5 128.3 ± 8
E2 24.2 ± 0.5 113.3 ± 9
Diabetes 16 Oil 41.0 ± 3.4* 356.6 ± 38*
E2 44.1 ± 1.8* 138.3 ± 20#
Comparisons between indicated phenotype and systemic endocrine/metabolic parameters in control, diabetes- or obese-mutant C57BK/KsJ mice 
at 8 and 16 weeks of age are demoted as group means (± SEM) for the designated number (N) of animals per group. Significant (P ≤ 0.05) intergroup 
differences (i.e. control v.s. genotype group values) at the designated age are indicated by asterisks (*).BMC Musculoskeletal Disorders 2006, 7:10 http://www.biomedcentral.com/1471-2474/7/10
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expression indices [2,3,5,6], the severity of expressed met-
abolic dysregulation is recognized to have a detrimental
influence on cellular proliferation, metabolic homeostasis
and osteostructural integrity, as well as the premature
onset of cytoapoptosis, nuclear dissolution and subse-
quent organoinvolution [18,28-30]. As indicated for pan-
creatic [17], renal [43], hepatic [16,44], reproductive tract
[28,29] and central nervous system [30,44-48] responses
to dysregulated db/db-syndrome microenvironments, dia-
betes-affected cellular differentiation, proliferation and
maturation indices are compromised, resulting in growth
abnormalities and restricted lifespan expectancies
[16,18,30,49]. In both the db/db and ob/ob groups, expres-
sion of the genotype mutations resulted in a severe hyper-
caloric, endocrine/metabolic disruption of normal VC
and LV osteodevelopmental patterns [16,18]. These
cytometabolic perturbations are recognized to be the
result of the deleterious chronic, progressive influences on
osteodevelopment [18,20,21], and have been associated
with Type 2 (NIDDM) insulin resistance (insensitivity) in
both animal models and humans exhibiting hyperglyc-
emia and hyperinsulinemia [18,50-52]. Thus, in skeletal
tissue affected by these cellular metabolic disturbances,
altered growth expression rates would expectedly influ-
ence bone maturation (growth) indices as demonstrated
by the db/db and ob/ob mutant groups. Associated with the
continued duration of mutation expression (i.e. 8 to 16
weeks), the severity of skeletal compromise would be
exacerbated [8,31,33] as cellular metabolic dysregulation
[4,6,10,31,36,37] progressively expanded into uncom-
promised tissue areas. As in humans [8,11,32-34], the
long-term exposure to metabolic compromise would
gradually influence the integrity and structural stability of
the osteoid matrix, decreasing tensile strength as a reflec-
tion of altered cytochemical composition
[1,5,6,8,10,39,51,52] and viable cellular densities
[2,4,6,10,13], increasing fracture susceptibility [35,38]
and promoting chronic skeletal deformation [8,31,50].
The efficacy and mechanisms of action of E2 and related
anti-osteoporosis therapeutic agents that exhibit systemic
glucose normalization capabilities [10,24,25,39,40,52],
under the continued deleterious influences of genotype
mutation expressions, are currently being evaluated for
osteo- maintenance/genesis properties.
Conclusion
In summary, the current studies define the variable influ-
ences of db/db and ob/ob genotype mutations on VC and
LV 1–5 osteomaturation indices, and the structural com-
promise in LV width indices promoted by these dysregu-
lated expression syndromes. Of particular interest were
the structural elongation of VC and LV 1–5 osteomatura-
tion parameters, and LV 1–5 width restrictions, in db/db
and ob/ob mutants associated with the hypercaloric meta-
bolic state that characterized both mutation syndromes.
Although altered vertebral width expression occurred
under such aberrant metabolic syndrome conditions, the
therapeutic normalization of systemic glucose concentra-
tions by E2-HRx stimulated LV osteodevelopment (width
indices) comparable to control parameters. The chronic
influences of these metabolic syndromes on progressive
VC and LV osteodevelopment are regarded as intrinsic
components of expressed skeletal compromise associated
with altered bone cellular proliferation rates, density,
cytochemical composition and diminished skeletal
strength exhibited by both humans and experimental
models exhibiting similar dysregulated metabolic syn-
dromes [16-18,25,27]. The results of these studies suggest
that these genetic models may be suitable for the further
evaluation of novel manipulative or therapeutic treat-
ments for osteomoderating events which are expressed in
similar dysregulated metabolic-based human syndromes.
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